Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interstitial Lung Disease
Interventions
- DRUG: Tulisokibart
- DIAGNOSTIC_TEST: Companion diagnostic ( CDx)
- DRUG: Placebo
Sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)